胰高血糖素样肽-1受体激动剂在2型糖尿病患者心血管并发症中的研究进展  

Research progress of glucagon like peptide 1 receptor agonist in cardiovascular complications of type 2 diabetic patients

作　　者：田国卫[1] 夏豪[1] 

机构地区：[1]武汉大学人民医院心血管内科,430060

出　　处：《疑难病杂志》2018年第1期86-90,共5页Chinese Journal of Difficult and Complicated Cases

基　　金：国家自然科学基金资助项目(81270184)

摘　　要：随着人口老龄化、肥胖以及生活方式的改变,糖尿病的发病率逐年上升。心血管并发症是2型糖尿病(T2DM)的重要并发症之一。在成年人中,2型糖尿病患者发生冠心病死亡事件的风险是非糖尿病患者的2~4倍。胰高血糖素样肽-1(GLP-1)受体激动剂代表新一代的降糖药物可使糖尿病患者得到很大的心血管获益。该文意在从生物学机制的角度来阐述GLP-1受体激动剂在治疗2型糖尿病同时带给患者的多方面的心血管获益。Currently, with the improvement of population aging, increased frequency of obesity and the change of lifestyle. Morbidity of diabetes meltitus （DM） is gradually with raising trend. Coronary heart disease （CHD） is .one of the major complication of DM. Among adults with diabetes, CHD death rates are 2-4 folds higher than the rates for adults without diabetes. Glucagon like peptide 1 （ GLP-1 ） receptor agonists represent a novel class of anti -hypergfycemic agents that have a significantly cardiac friendly profile： This brief review is intended to rationally review the multifactorial cardiovascular effects of glucagon like peptide 1 receptor agonists for the treatment of patients with type 2 diabetes from the biological mechanisms.

关 键 词：胰高血糖素样肽-1 2型糖尿病 心血管疾病 

分 类 号：R54[医药卫生—心血管疾病] R587.2[医药卫生—内科学]